BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2202336)

  • 1. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris.
    Kemény L; Ruzicka T; Braun-Falco O
    Skin Pharmacol; 1990; 3(1):1-20. PubMed ID: 2202336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone).
    Mustakallio KK; Brandt H
    Acta Derm Venereol; 1984; 64(1):63-6. PubMed ID: 6203285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis].
    Sander P; Happe M; Stücker M; Hermes N; Hoffmann K; Altmeyer P
    Hautarzt; 1999 Oct; 50(10):723-7. PubMed ID: 10550358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriasis with anthrones-chemical principles, biochemical aspects, and approaches to the design of novel derivatives.
    Wiegrebe W; Müller K
    Skin Pharmacol; 1995; 8(1-2):1-24. PubMed ID: 7786521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). II. Clinical comparison of dithranol and butantrone sticks with special reference to side effects.
    Brandt H
    Acta Derm Venereol; 1987; 67(1):55-61. PubMed ID: 2436415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-contact therapy for psoriasis with 3.9% butantrone (10-butyryl dithranol).
    Remitz A
    Acta Derm Venereol; 1989; 69(4):351-4. PubMed ID: 2568062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid.
    Swinkels OQ; Prins M; Kucharekova M; de Boo T; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Br J Dermatol; 2002 Apr; 146(4):621-6. PubMed ID: 11966693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immunohistochemical assessment of the response of the psoriatic lesion to single and repeated applications of high-dose dithranol cream.
    Swinkels OQ; Prins M; Gerritsen MJ; van Vlijmen-Willems IM; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):393-400. PubMed ID: 12476013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals.
    Müller K
    Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dithranol on neutrophil superoxide generation in patients with psoriasis.
    Kavanagh GM; Burton JL; Donnell VO
    Br J Dermatol; 1996 Feb; 134(2):234-7. PubMed ID: 8746335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free radicals and the treatment of psoriasis with special reference to dithranol.
    Mustakallio KK; Martinmaa J; Vilvala R; Halmekoski J
    Med Biol; 1984; 62(2):155-8. PubMed ID: 6471937
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antipsoriatic effect of dithranol (anthralin). 1].
    Raab W
    Hautarzt; 1975 Sep; 26(9):452-5. PubMed ID: 1184389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes.
    Holstein J; Fehrenbacher B; Brück J; Müller-Hermelink E; Schäfer I; Carevic M; Schittek B; Schaller M; Ghoreschi K; Eberle FC
    J Dermatol Sci; 2017 Sep; 87(3):236-245. PubMed ID: 28673488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of a topical corticosteroid on short-contact high-dose dithranol therapy.
    Swinkels OQ; Prins M; Tosserams EF; Gerritsen MJ; Van Der Valk PG; Van De Kerkhof PC
    Br J Dermatol; 2001 Jul; 145(1):63-9. PubMed ID: 11453908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urea in combination with dithranol in treating psoriasis vulgaris].
    Przybilla B; Kaudewitz P; Bieber K
    Hautarzt; 1989; 40 Suppl 9():54-7. PubMed ID: 2681078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response and side-effects in the treatment of psoriasis with UV-B and -A novel dithranol formulation.
    Christensen OB; Holst R; Hradil E; Brolund L
    Acta Derm Venereol Suppl (Stockh); 1989; 146():96-100; discussion 101. PubMed ID: 2609898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of psoriasis with dithranol cream compared with dithranol paste.
    Young E
    Dermatologica; 1986; 173(6):285-7. PubMed ID: 3817239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp.
    Wulff-Woesten A; Ohlendorf D; Henz BM; Haas N
    Skin Pharmacol Physiol; 2004; 17(2):91-7. PubMed ID: 14976386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of epidermal growth factor receptors by dithranol.
    Kemény L; Michel G; Arenberger P; Ruzicka T
    Acta Derm Venereol; 1993 Feb; 73(1):37-40. PubMed ID: 8095749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dithranol and butantrone in short contact therapy of psoriasis.
    Göransson A
    Acta Derm Venereol; 1987; 67(2):149-53. PubMed ID: 2438880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.